(S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione

(S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione Suppliers list
Company Name: 3B Pharmachem (Wuhan) International Co.,Ltd.  
Tel: 18930552037
Email: 3bsc@sina.com
Company Name: EMMX Biotechnology LLC  
Tel: 888-539-0666
Email: info@emmx.com
Company Name: Jinan Yaoyan Pharmaceutical Co., Ltd.  
Tel:
Email: jnyaoyan@163.com
Company Name: Fan De(Beijing) Biotechnology Co., Ltd.  
Tel: 15911056312
Email: liming@bio-fount.com
Company Name: Nanjing Meihao Pharmaceutical Technology Co., Ltd.  
Tel: meitaochem@126.com
Email: meitaochem@126.com

(S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione manufacturers

  • UBP 302
  • UBP 302 pictures
  • $198.00
  • 2026-05-11
  • CAS:745055-91-8
  • Purity:
  • Supply Ability: 10g
(S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione Basic information
Product Name:(S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione
Synonyms:2-[[3-[(2S)-2-amino-2-carboxyethyl]-2,6-dioxopyrimidin-1-yl]methyl]benzoic acid;UBP302, PUBCHEM CID: 6420161;UBP 302;(αS)-α-amino-3-[(2-carboxyphenyl)methyl]-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinepropanoic acid;1(2H)-Pyrimidinepropanoic acid, α-amino-3-[(2-carboxyphenyl)methyl]-3,4-dihydro-2,4-dioxo-, (αS)-;(S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione
CAS:745055-91-8
MF:C15H15N3O6
MW:333.3
EINECS:
Product Categories:Glutamate receptor
Mol File:Mol File
(S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione Structure
(S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione Chemical Properties
Melting point 207.9-208.5 °C (decomp)(Solv: water (7732-18-5))
Boiling point 603.0±65.0 °C(Predicted)
density 1.525±0.06 g/cm3(Predicted)
storage temp. Store at RT
solubility DMSO: ≥5mg/mL at 60°C (with warming for 5 minutes)
pka2.12±0.10(Predicted)
form powder
color white to off-white
InChI1S/C15H15N3O6/c16-11(14(22)23)8-17-6-5-12(19)18(15(17)24)7-9-3-1-2-4-10(9)13(20)21/h1-6,11H,7-8,16H2,(H,20,21)(H,22,23)/t11-/m0/s1
InChIKeyUUIYULWYHDSXHL-NSHDSACASA-N
SMILESN[C@@H](CN1C=CC(=O)N(Cc2ccccc2C(O)=O)C1=O)C(O)=O
Safety Information
Hazard Codes Xn
Risk Statements 22
WGK Germany 3
Storage Class11 - Combustible Solids
Hazard ClassificationsAcute Tox. 4 Oral
MSDS Information
(S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione Usage And Synthesis
DescriptionUBP 302 is an antagonist of glutamate receptor 5 (GluR5) subunit-containing kainate receptors that inhibits kainate-induced responses in isolated rat dorsal roots (Kd = 402 nM). In vitro, UBP 302 inhibits gamma frequency oscillations in the rat basolateral amygdala at a concentration of 25 μM, and blocks kainate receptor signaling in layer III neurons within the mouse medial entorhinal cortex at 20 μM, abrogating the intense synaptic activity characteristic of the Up state of cortical slow oscillation. In vivo, UBP 302 (250 mg/kg) significantly reduces seizure severity in a rat model of soman-induced status epilepticus.
UsesUBP 302 is a potent and selective GLUK5 receptor antagonist.
Biological ActivitySelective and potent GLU K5 (GluR5)-subunit containing kainate receptor antagonist (apparent K D = 402 nM); active enantiomer of UBP 296 ((RS)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione ). Displays ~ 260-fold selectivity over AMPA receptors. UBP 296 displays ~ 90-fold selectivity over recombinant human GLU K6 - and GLU K2 -containing kainate receptors, has little or no action at NMDA or group I mGlu receptors and selectively blocks kainate receptor-mediated LTP induction in rat hippocampal mossy fibres.
storageRoom temperature
References[1] JULIA C.A. MORE . Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist[J]. Neuropharmacology, 2004, 47 1: Pages 46-64. DOI: 10.1016/j.neuropharm.2004.03.005
[2] FIONA E. RANDALL  Mark O C  Miles A Whittington. Fast oscillatory activity induced by kainate receptor activation in the rat basolateral amygdala in vitro[J]. European Journal of Neuroscience, 2011, 33 5: 914-922. DOI: 10.1111/j.1460-9568.2010.07582.x
[3] RICHARD J. DIGBY . Distinct mechanisms of Up state maintenance in the medial entorhinal cortex and neocortex[J]. Neuropharmacology, 2017, 113: Pages 543-555. DOI: 10.1016/j.neuropharm.2016.11.009
[4] STEVEN L. MILLER . A rat model of nerve agent exposure applicable to the pediatric population: The anticonvulsant efficacies of atropine and GluK1 antagonists[J]. Toxicology and applied pharmacology, 2015, 284 2: Pages 204-216. DOI: 10.1016/j.taap.2015.02.008
(S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione Preparation Products And Raw materials
Tag:(S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione(745055-91-8) Related Product Information
UBP301 hydrochloride (RS)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione (S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione (αS)-alpha-amino-3-[(4-carboxyphenyl)methyl]-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinepropanoic acid (αS)-alpha-amino-3-[(4-carboxyphenyl)methyl]-3,4-dihydro-5-iodo-2,4-dioxo-1(2H)-pyrimidinepropanoic acid Lanicemine dihydrochloride